ArticleProceedings of the National Academy of Sciences of the United States of America2003
Yeast genetic selections to optimize RNA decoys for transcription factor NF-kappa B.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 62 citations in OpenAlex.
- Decoy oligonucleotides targeting NF-κB: a promising therapeutic approach for inflammatory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Review
- Cancer immunomodulation using bispecific aptamers.Molecular therapy. Nucleic acids · 2022Review
- Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application.Molecules (Basel, Switzerland) · 2019Review
- Aptamers: Uptake mechanisms and intracellular applications.Advanced drug delivery reviews · 2018Review
- Anti-Transcription Factor RNA Aptamers as Potential Therapeutics.Nucleic acid therapeutics · 2016Review
- RNA aptamer inhibitors of a restriction endonuclease.Nucleic acids research · 2015Article
- Challenges and opportunities for small molecule aptamer development.Journal of nucleic acids · 2012Article
- Evolution of an inhibitory RNA aptamer against T7 RNA polymerase.FEBS open bio · 2012Article
- Using the Yeast Three-Hybrid System to Identify Proteins that Interact with a Phloem-Mobile mRNA.Frontiers in plant science · 2012Article
- Engineering biological systems with synthetic RNA molecules.Molecular cell · 2011Review
- Knocking down gene function with an RNA aptamer expressed as part of an intron.Nucleic acids research · 2010Article
- In vitro and ex vivo selection procedures for identifying potentially therapeutic DNA and RNA molecules.Molecules (Basel, Switzerland) · 2010Review
- An RNA-based transcription activator derived from an inhibitory aptamer.Nucleic acids research · 2010Article
- Selections that optimize RNA display in the yeast three-hybrid system.RNA (New York, N.Y.) · 2010Review
- Characterization of anti-NF-kappaB RNA aptamer-binding specificity in vitro and in the yeast three-hybrid system.Nucleic acids research · 2009Article
- Therapeutic applications of DNA and RNA aptamers.Oligonucleotides · 2009Review
- Selection and characterization of anti-NF-kappaB p65 RNA aptamers.RNA (New York, N.Y.) · 2008Article
- DNA mimicry by a high-affinity anti-NF-kappaB RNA aptamer.Nucleic acids research · 2008Article
- Combining SELEX and the yeast three-hybrid system for in vivo selection and classification of RNA aptamers.RNA (New York, N.Y.) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vitro-selected RNA aptamers are potential inhibitors of disease-related proteins. Our laboratory previously isolated an RNA aptamer that binds with high affinity to human transcription factor NF-kappaB. This RNA aptamer competitively inhibits DNA binding by NF-kappaB in vitro and is recognized by its target protein in vivo in a yeast three-hybrid system. In the present study, yeast genetic selections were used to optimize the RNA aptamer for binding to NF-kappaB in the eukaryotic nucleus. Selection for improved binding to NF-kappaB from RNA libraries encoding (i) degenerate aptamer variants and (ii) sequences present at round 8 of 14 total rounds of in vitro selection yielded RNA aptamers with dramatically improved in vivo activity. Furthermore, we show that an in vivo-optimized RNA aptamer exhibits specific "decoy" activity, inhibiting transcriptional activation by its NF-kappaB target protein in a yeast one-hybrid assay. This decoy activity is enhanced by the expression of a bivalent aptamer. The combination of in vitro and in vivo genetic selections was crucial for obtaining RNA aptamers with in vivo decoy activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.